Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antibody directed enzymes revive anti-cancer prodrugs concept.

Literature DB >> 3426915

Antibody directed enzymes revive anti-cancer prodrugs concept.

K D Bagshawe¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1987 PMID： 3426915 PMCID： PMC2001889 DOI： 10.1038/bjc.1987.237

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

× No keyword cloud information.

10 in total

1. Reduction of cytotoxic azo compounds by hydrazine and by the xanthine oxidase-xanthine system.

Authors: W C ROSS; G P WARWICK
Journal: Nature Date: 1955-08-13 Impact factor: 49.962

2. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.

Authors: G J Jaffers; T C Fuller; A B Cosimi; P S Russell; H J Winn; R B Colvin
Journal: Transplantation Date: 1986-05 Impact factor: 4.939

3. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells.

Authors: J J Roberts; F Friedlos; R J Knox
Journal: Biochem Biophys Res Commun Date: 1986-11-14 Impact factor: 3.575

4. Recombinant antibodies possessing novel effector functions.

Authors: M S Neuberger; G T Williams; R O Fox
Journal: Nature Date: 1984 Dec 13-19 Impact factor: 49.962

5. Cancer drug targeting.

Authors: K D Bagshawe
Journal: Clin Radiol Date: 1985-11 Impact factor: 2.350

6. 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

Authors: L M Cobb; T A Connors; L A Elson; A H Khan; B C Mitchley; W C Ross; M E Whisson
Journal: Biochem Pharmacol Date: 1969-06 Impact factor: 5.858

7. Protease-activated "prodrugs" for cancer chemotherapy.

Authors: P L Carl; P K Chakravarty; J A Katzenellenbogen; M J Weber
Journal: Proc Natl Acad Sci U S A Date: 1980-04 Impact factor: 11.205

8. Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour.

Authors: T A Connors; D H Melzack
Journal: Int J Cancer Date: 1971-01-15 Impact factor: 7.396

9. The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro.

Authors: F Searle; C Bier; R G Buckley; S Newman; R B Pedley; K D Bagshawe; R G Melton; S M Alwan; R F Sherwood
Journal: Br J Cancer Date: 1986-03 Impact factor: 7.640

10. Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?

Authors: K D Bagshawe
Journal: Br J Cancer Date: 1983-08 Impact factor: 7.640

10 in total

50 in total

Review 1. Targeted prodrug design to optimize drug delivery.

Authors: H K Han; G L Amidon
Journal: AAPS PharmSci Date: 2000

Review 2. Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors: C H Ford; V J Richardson; V S Reddy
Journal: Indian J Pediatr Date: 1990 Jan-Feb Impact factor: 1.967

Review 3. Enzymes as Immunotherapeutics.

Authors: Shaheen A Farhadi; Evelyn Bracho-Sanchez; Sabrina L Freeman; Benjamin G Keselowsky; Gregory A Hudalla
Journal: Bioconjug Chem Date: 2018-01-31 Impact factor: 4.774

Review 4. ADEPT and related concepts.

Authors: K D Bagshawe
Journal: Cell Biophys Date: 1994

5. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.

Authors: C J Springer; G K Poon; S K Sharma; K D Bagshawe
Journal: Cell Biophys Date: 1994